KRAS and pancreatic ductal adenocarcinoma: Recently Chan et al. (34) reported an interesting study on the identification of sotorasib (AMG 510) resistance in the KRAS G12C-mutant MIA-PaCa2 pancreatic ductal adenocarcinoma cells when treated with increasing dosage (0.1–5 μM) for 60 days and found that MIA-PaCa2 showed resistance at 5 μM treatment of AMG 510 (34).